PCP
NKTR icon

Proficio Capital Partners’s Nektar Therapeutics NKTR Stock Holding History

Proficio Capital Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4
Closed -$2K – 1041
2019
Q2 		$2K Sell
4
-2
-33% -$1K ﹤0.01% 1566
2019
Q1 		$3K Hold
6
– – ﹤0.01% 1261
2018
Q4 		$3K Buy
+6
New +$3.62K ﹤0.01% 964
2018
Q3 		– Sell
-2
Closed -$1K – 1285
2018
Q2 		$1K Buy
+2
New +$2.31K ﹤0.01% 1213

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Proficio Capital Partners's NKTR Position: Q3 2019 in Review

Proficio Capital Partners sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 4 shares — an estimated $2K sold.

Proficio Capital Partners first reported a position in NKTR in Q2 2018 and held it in 4 quarters. The position peaked at $3K in Q1 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Proficio Capital Partners reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 4 Nektar Therapeutics shares in Q3 2019, an estimated $2K.
  • Proficio Capital Partners first reported a position in Nektar Therapeutics in Q2 2018 and held it in 4 quarters.
  • Proficio Capital Partners's Nektar Therapeutics position peaked at $3K in Q1 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.